Iovance Biotherapeutics (IOVA) Gross Profit (2023 - 2026)

Iovance Biotherapeutics (IOVA) has reported Gross Profit for 4 consecutive years, with $28.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Profit rose 337.77% year-over-year to $28.9 million; the TTM figure through Mar 2026 stood at $104.9 million (up 51.33% YoY), while the FY2025 annual figure was $90.3 million, up 27.53% from the prior year.
• Gross Profit eased to $28.9 million in Q1 2026 per IOVA's latest filing, from $43.7 million in the prior quarter.
• Across five years, Gross Profit topped out at $43.7 million in Q4 2025 and bottomed at -$6.5 million in Q1 2024.
• Historically, Gross Profit has averaged $14.0 million across 4 years, with a median of $6.2 million in 2023.
• On a YoY basis, Gross Profit climbed as much as 1354.96% in 2025 and fell as far as 7.18% in 2025.
• Iovance Biotherapeutics' Gross Profit stood at $5.8 million in 2023, then soared by 514.92% to $35.9 million in 2024, then grew by 21.6% to $43.7 million in 2025, then tumbled by 33.73% to $28.9 million in 2026.
• Business Quant data shows IOVA's Gross Profit at $28.9 million in Q1 2026, $43.7 million in Q4 2025, and $29.0 million in Q3 2025.